Targeted Therapy for the Central Nervous System

Part I. Brief About Pathophysiology1. Etiology and Treatment Challenges for Neurodegenerative Disorders2. Etiology and Treatment Challenges for Neurotraumatic and Psychiatric Disorders3. Barriers to Progress of Neurotherapeutics: Getting Drugs to the Brain Part II. Novel Formulation Strategies for Targeted Therapy4. IGF-II Conjugated Nanocarrier for Brain Targeting5. ApoE Potential in CNS Drugs Targeting and as CNS Therapeutic6. Transferrin Functionalized Nanoparticles for Targeted Drug Delivery in Biological Systems7. Surface Engineered Multimodal Magnetic Nanoparticles for Neurodegenerative Diseases8. Tau Targeting Biomimetic Nanoparticles 9. Stem Cell Therapy as a Novel Concept to Combat CNS Disorders10. SR-B1 Receptor Targeting in CNS Disorders11. ß- and ¿-secretases as Therapeutic Targets for Alzheimer's Disease12. Minimally Invasive Nasal Depot (MIND) Technique for Direct BDNF AntagoNAT Delivery to the Brain13. Immunosuppressive and Immunomodulatory Therapies14. CRISPR/Cas9 Gene Editing: A New Hope for Alzheimer's Disease15. Artificial Intelligence: Ways and Means for Central Nervous System (CNS) Delivery16. Carbon Dots as Versatile Nano-architectures for the Treatment of Neurological Disorders Part III. Clinical Challenges and Regulatory Updates17. Animal Models for Clinical Evaluation18. Medical Device Contributors: Abhishek Swarnkar, Viral Patel, Amit Patel, Manan Raval19. Regulation of Nanomaterials and Nanomedicines for Clinical Applications20. Regulatory Considerations for the use of Biomarkers and Personalized Medicine in CNS Drug Development21. Regulatory Toxicology Testing for Pharmaceuticals22. Emerging Challenges and Opportunities for Drug and Drug Product Registrations23. CRISPR/Cas9 Gene Editing: A New Hope for Parkinson's Disease